Oncoinvent Launches 100-for-1 Reverse Share Split and New ISIN on Oslo Bourse

The latest announcement is out from BerGenBio ASA ( (BRRGF) ).

Oncoinvent ASA has approved and scheduled a 100-for-1 reverse share split, effective from 19 January 2026, which will consolidate every 100 existing shares into one new share and raise the par value from NOK 0.50 to NOK 50, with trading shifting to a new ISIN on the same date. Shareholders whose holdings are not divisible by 100 will have their positions rounded down without compensation, with aggregated fractional shares to be sold on the Oslo Stock Exchange and net proceeds donated to charity, a move that simplifies the company’s capital structure and could improve share tradability and perception among investors.

More about BerGenBio ASA

Oncoinvent ASA is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer. Its lead product candidate, Radspherin, is an investigational alpha-emitting radium-224-based therapy designed for local treatment of micro-metastatic disease in body cavities, particularly peritoneal carcinomatosis from ovarian and colorectal cancer, administered intraperitoneally after tumor-resecting surgery. The company has completed early-phase clinical trials, is running a randomized Phase 2 study in the US, UK and Europe with encouraging efficacy and safety data so far, and operates a state-of-the-art manufacturing facility in Oslo, employing around 40 people and listing its shares on the Oslo Stock Exchange.

Average Trading Volume: 1,415,585

Current Market Cap: NOK208.2M

Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.